Accession Number:

ADA460789

Title:

Regulation of T-Type Cyclin/CDK9 Complexes in Breast Cancer Cells

Descriptive Note:

Annual summary rept. 1 Jul 2002-31 Jun 2005

Corporate Author:

TEMPLE UNIV PHILADELPHIA PA

Personal Author(s):

Report Date:

2005-07-01

Pagination or Media Count:

9.0

Abstract:

Positive transcription elongation b P-TEFb is a general transcription elongation factor and is composed of a catalytic subunit, CDK9, and a regulatory subunit, a T-type cyclin. The complex phosphorylates the C-terminal domain of RNA polymerase II as well as negative elongation factors to allow for the transcriptional elongation of paused transcripts. We have investigated the regulation and role of cyclin T1 in breast cancer cells. While cyclin T1 expression is regulated by multiple signaling pathways in T cells, it is constitutively expressed in breast cancer cells. Also, cyclin T1 associated kinase activity is not regulated in PMA treated MCF-7 and T47D cells. Flavopiridol FVP, a drug being evaluated in clinical trials as an anti-cancer agent, and a potent inhibitor of HIV transcription, is believed to act, at least in part, by inhibiting CDK9. We have compared the effects of FVP with those effects induced by direct inhibition of CDK9 by a dominant negative dnCDK9 in breast cancer cells and found that both treatments result in p53-independent apoptosis of breast cancer cells.

Subject Categories:

  • Biochemistry
  • Genetic Engineering and Molecular Biology
  • Anatomy and Physiology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE